HC Wainwright set a $10.00 price objective on Agile Therapeutics, Inc. (NASDAQ:AGRX) in a research note released on Thursday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
A number of other analysts also recently issued reports on the stock. Royal Bank Of Canada set a $8.00 price target on shares of Agile Therapeutics and gave the stock a buy rating in a report on Sunday, July 16th. Janney Montgomery Scott reissued a buy rating and set a $15.00 price target on shares of Agile Therapeutics in a report on Friday, July 21st. ValuEngine raised shares of Agile Therapeutics from a strong sell rating to a sell rating in a report on Saturday, July 8th. Noble Financial reissued a buy rating on shares of Agile Therapeutics in a report on Wednesday, June 14th. Finally, Cantor Fitzgerald reissued an overweight rating and set a $8.00 price target on shares of Agile Therapeutics in a report on Thursday, September 21st. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Agile Therapeutics has an average rating of Buy and an average price target of $10.20.
Agile Therapeutics (NASDAQ:AGRX) traded down 5.46% on Thursday, reaching $5.02. 268,486 shares of the company’s stock traded hands. Agile Therapeutics has a 12-month low of $1.82 and a 12-month high of $7.80. The stock has a 50 day moving average price of $4.01 and a 200 day moving average price of $3.72. The stock’s market cap is $144.61 million.
Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings data on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.02. During the same quarter in the previous year, the company earned ($0.29) earnings per share. Analysts forecast that Agile Therapeutics will post ($1.02) EPS for the current year.
In other news, Chairman Alfred Altomari purchased 10,000 shares of the stock in a transaction that occurred on Friday, August 25th. The shares were purchased at an average cost of $3.34 per share, with a total value of $33,400.00. Following the completion of the acquisition, the chairman now owns 161,587 shares of the company’s stock, valued at approximately $539,700.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 3.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in AGRX. Royal Bank of Canada boosted its holdings in Agile Therapeutics by 608.0% during the second quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock worth $122,000 after buying an additional 27,907 shares in the last quarter. Janney Montgomery Scott LLC acquired a new position in Agile Therapeutics during the second quarter worth $122,000. Susquehanna International Group LLP acquired a new position in Agile Therapeutics during the second quarter worth $205,000. LMR Partners LLP acquired a new position in Agile Therapeutics during the second quarter worth $211,000. Finally, Goldman Sachs Group Inc. acquired a new position in Agile Therapeutics during the second quarter worth $309,000. 67.59% of the stock is currently owned by hedge funds and other institutional investors.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.